After FTC scrutiny of Sanofi deal, Maze finds a new Pompe partner in Shionogi

Maze Ther­a­peu­tics has found a new buy­er for its Pompe dis­ease can­di­date, five months af­ter scruti­ny from the Fed­er­al Trade Com­mis­sion led Sanofi to back out of a deal for the clin­i­cal-stage drug.

The new li­censee is Sh­iono­gi, the com­pa­nies said Fri­day morn­ing. The Os­a­ka, Japan-based phar­ma will dish out $150 mil­lion up­front and pay an undis­closed amount in biobucks. Al­most a year ago to the day, Maze dis­closed that Sanofi would dole out the same amount up­front for the oral can­di­date and could pay an­oth­er $600 mil­lion in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.